Skip to main content

and
  1. Article

    Open Access

    Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial

    New immuno-oncology therapies targeting programmed cell death receptor 1 (PD-1) have improved patient outcomes in a broad range of cancers. The objective of this analysis was to evaluate the PK, pharmacodynami...

    Amita Patnaik, Glen J. Weiss, Drew W. Rasco in Cancer Chemotherapy and Pharmacology (2022)

  2. No Access

    Chapter

    Update on Precision Medicine in Breast Cancer

    Precision medicine approaches have found applications in the treatment of several tumor types and have led to rapid advancement in the number of available therapies for some difficult-to-treat diseases. In com...

    Jasgit C. Sachdev, Ana C. Sandoval in Precision Medicine in Cancer Therapy (2019)